| Name | Title | Contact Details |
|---|
Rescale provides the largest, most secure, global HPC footprint seamlessly integrated into an easy-to-use platform built for engineers and scientists.
The future of B2B marketing is product-led and at Inflection.io, we believe this new end-user area will require innovative solutions that are purposefully built for product-led companies. Inflection.io puts product activity data at the center of solution design and optimizes for the scalability and extensibility demands of the modern product-led marketing team. We`re also the team behind ProductLed.Marketing, the #1 community dedicated to marketing and product-led growth with nearly 1,000 members. We`re backed by top firms including MHS Capital, Version One, Vulcan, and a stellar group of angel investors, including: Matt Heinz (CRO Amplitude, SVP Sales Marketo), Edward Unthank (CEO Etumos), Justin Gray (CEO LeadMD), Adam Schoenfeld (CEO Simply Measured, VP Strategy Drift), Ray Carroll (VP Sales Marketo, VP Sales Engagio), Brewster Stanislaw (VP Product Bizible, Marketo, CPO Demandbase), Patrick Thompson (CEO Iteratively, Dir. Product Amplitude), and many more. Operating out of Seattle, Kochi, Bengaluru, Pune, Chennai, and many more cities to come, we`re a team that values creating value for customers, growth (including careers), being treated fairly, impact, ownership, and teamwork. We`re always hiring and we encourage you to see our open roles, especially if you come from a diverse or non-traditional background.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Cisive is a leading global background screening provider focused on providing high-value employment background checks and industry-specific compliance services to highly regulated, risk-sensitive industries. Cisive has long-term relationships with a diverse base of clients across healthcare, financial services, transportation and other regulated industries. Founded in 1977, Cisive has developed a broad range of differentiated vertical business lines and risk mitigation offerings including the core Cisive brand (global and enterprise), PreCheck (healthcare), Driver iQ (trucking and transportation), eVerifile (rail and contractor), Inquiries Screening (government), IntelliCorp (small and mid-market) and CARCO (insurance risk mitigation). Cisive`s solutions deliver compliant employment intelligence to employers who are highly averse to employee-related risks and operate in highly regulated industries. With Cisive, your business will not only gain a background screening provider, but a true partnership: a company that stands by our work, protects our clients, and provides the consultation and guidance world-class organizations seek.
Dramatically shorten your exposure during a cyber incident. Turn your companys incident reponse into instant response with CyFIR forensics analysis and incident response software.